Daniel Simão is an experienced researcher currently serving as the Head of the Bayer Pharma Satellite Lab at iBET - Instituto de Biologia Experimental e Tecnológica since July 2017. Prior to this role, Daniel held positions as a Senior Researcher at the same lab and as a Post-Doc Research Fellow at ITQB-UNL, where research focused on human hepatic cell models and neural stem cell differentiation. Earlier experience includes postdoctoral research at the Institut de Génétique Moléculaire de Montpellier, optimizing gene transfer vectors, and a PhD candidacy in Bioengineering Systems as part of the MIT Portugal Program, specializing in human neural in vitro models. Daniel's academic credentials feature a PhD from Universidade Nova de Lisboa, along with a Master's in Molecular Biology and Biomedicine, and a Licentiate degree in Molecular Biology.
iBET - Instituto de Biologia Experimental e Tecnológica
iBET is a private non-profit research institution specialized in biotechnology research and bioprocess development. iBET acts as an interface between academia and industry while also creating and organizing autonomous knowledge. Our expertise includes the development of bioprocesses for complex biopharmaceuticals and advanced therapies, including vaccines, recombinant proteins, and viral vectors for gene and onco- therapy, stem cells for cell therapy applications; development of in-vitro cell models and protocols for pre-clinical research; analytical tools for quality control of biologics; and structural biology for assisted drug design. Within Food and Health, we develop new solutions for the detection of food frauds, food and water-borne pathogens, and work on the discovery of new bioactive food supplements. To address some environmental issues, we also develop new sustainable, energy saving, processes for both food and water industries. iBET’s infrastructure comprises more than 20 R&D laboratories, a GMP certified Analytical Services Unit, a Mass Spectrometry Unit and a Late-Stage R&D and Bioproduction Unit (2000m2). The new iBET Biofarma building added 29 laboratories to its research and analytical platform infrastructure, including one BLS3 Lab. As an R&D institution, iBET has coordinated over 30 international projects and participated as work-package leader in more than 100 EU-funded projects. iBET has also been involved in some of the most prestigious RD&I and technology transfer projects, with remarkable international impact and has several well established collaborations in Networks of Excellence and with international pharmaceutical companies, such as Bayer, Novartis, Merck, Abbvie, Sanofi, Apceth, AstraZeneca, Glaxo-Smith-Kline , Merck & Co., among others. iBET’s success relies heavily on its large staff of over 250 people, of which about 110 have a PhD degree, and who contribute with advanced skills and experience to our areas of expertise.